Source Fact: Financial Supervisory Service DART / 2024-06-26
Disclosure Type: Major Management Matters Related to Investment Judgment (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement worth approximately KRW 91.4B, extending the contract period and the client confidentiality deadline by one month to July 31, 2024, per the client’s request.
📊 1. [Summary of Core Disclosure & Key Figures]
- Amended Original Disclosure: Major Management Matters Related to Investment Judgment initially submitted on December 23, 2021
- Contract Name: Conclusion of Letter of Intent (LOI) for Biopharmaceutical Contract Manufacturing
- Contract Amount: KRW 91,369,732,137 (Fixed amount: USD 76,703,939)
- Applied FX Rate: Fixed at KRW 1,191.20 per USD (The standard proxy rate on the initial disclosure date of December 23, 2021)
- Note: There is no value change in this specific amendment; the current amount reflects a prior increase of USD 20,122,939 from the initial USD 56,581,000 due to client request.
- Ratio to Revenue: 7.84% relative to the annual revenue baseline at the time of initial disclosure (KRW 1.16T)
- Counterparty: A pharmaceutical company located in Europe (Identity remaining confidential due to trade secrecy)
- Changes in Contract Period & Confidentiality Postponement:
- Pre-amendment: October 30, 2021 ~ June 30, 2024 (Same for disclosure withholding expiration)
- Post-amendment: October 30, 2021 ~ July 31, 2024 (Extended by 1 month; same for disclosure withholding expiration)
- Note: The designated contract value remains legally binding between both parties. Upon the execution of the definitive formal contract in the future, finalized updates will be re-disclosed.
📈 2. [Expert Insight: Implications for Investors]
- Contract Validity Maintained with Timeline Adjustment: This amendment involves no alterations to the total contract value, solely shifting the timeline and confidentiality expiration date at the client’s request. It signals that the LOI executed in 2021 remains fully legally effective and is likely undergoing scheduling adjustments prior to converting into a formal contract.
- Limited Immediate Financial Volatility: Because this is an administrative timeline shift for confidentiality rather than a cancellation or value reduction, the immediate impact on the company’s current financial Fundamental remains highly limited.
- Investor Consideration: The postponement represents a delay in the transition window from an LOI to a definitive contract, keeping the counterparty masked under confidentiality until late July 2024. As noted in the filing, this deadline remains subject to further change depending on negotiations, meaning market participants should monitor subsequent official filings for finalized contract conversion notices moving forward.
📝 Editor’s Comment (by K-STOCK Editor)
The closing window for the European CMO Letter of Intent (LOI), which has been active since late 2021, has been pushed back one month from the end of June to the end of July. While this extension does not impact the recorded order book value or indicate any structural flaw in Fundamental, it implies that the final fine-tuning between the two parties prior to signing the definitive agreement is ongoing. Commercial biopharma contracts involve complex variables—ranging from precise production slots to pricing and raw material sourcing protocols—leading to frequent administrative shifts. Investors should patiently track whether this adjusted timeline culminates in a fully finalized formal contract disclosure.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
